Tag: Bioxyne Limited
Bioxyne signs $5.6M supply agreement to enter German medical cannabis market
Bioxyne Limited), through its subsidiary Breathe Life Sciences (BLS), has entered the German medical cannabis market by securing a commercial supply agreement worth a minimum of €3.2 million (approximately AUD 5.6 million) for FY2026.
Bioxyne granted Australia’s first GMP licence for Psilocybin and MDMA manufacturing
Bioxyne Limited's subsidiary, Breathe Life Sciences (BLS), has secured the Good Manufacturing Practice (GMP) licence for the production of medical cannabis.
Featured Article
Smarter energy decisions: GridBeyond unveils AI-powered Bid Optimiser in Australia
As Australia’s energy transition accelerates, businesses participating in the National Electricity Market (NEM) are facing growing challenges in managing their energy assets efficiently.
